PRESS RELEASE published on 05/31/2024 at 15:51, 10 months 13 days ago DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies announces plan to change ADS Ratio to regain Nasdaq compliance effective June 7th, 2024, impacting ADS holders trading price Biopharmaceutical Company Nasdaq Compliance DBV Technologies ADS Ratio Change Food Allergies Treatment
BRIEF published on 05/17/2024 at 22:35, 10 months 27 days ago DBV Technologies Announces ADS Ratio Change Nasdaq Compliance Biopharmaceuticals Stock Adjustment DBV Technologies ADS Ratio Change
PRESS RELEASE published on 05/17/2024 at 22:30, 10 months 27 days ago DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies announces plan to change ADS Ratio to regain Nasdaq compliance. The ADS Ratio Change will be effective on June 3rd, 2024, impacting ADS trading price. No impact on underlying ordinary shares Ordinary Shares Nasdaq Compliance DBV Technologies ADS Ratio Change Trading Price
BRIEF published on 05/16/2024 at 22:35, 10 months 28 days ago DBV Technologies announces the results of the 2024 Combined General Meeting General Assembly 2024 DBV Technologies Resolutions Adopted Allergy Treatment Biopharmaceutical Sector
PRESS RELEASE published on 05/16/2024 at 22:30, 10 months 28 days ago DBV Technologies Announces Results of its 2024 Combined General Meeting DBV Technologies announces successful results of its 2024 Combined General Meeting where shareholders approved all proposed resolutions. The Company focuses on treatment options for food allergies Resolutions Combined General Meeting DBV Technologies Food Allergies Treatment Options
BRIEF published on 05/09/2024 at 22:35, 11 months 4 days ago DBV Technologies announces its participation in two investor conferences in May DBV Technologies Food Allergy JMP Life Sciences HC Wainwright BioConnect Conference Webcast
PRESS RELEASE published on 05/09/2024 at 22:30, 11 months 4 days ago DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies to participate in two upcoming investor conferences in May, presenting its clinical-stage biopharmaceutical developments. Learn more about their innovative treatment options Investor Conferences Biopharmaceutical DBV Technologies Food Allergies Immunologic Conditions
BRIEF published on 05/07/2024 at 22:35, 11 months 6 days ago DBV Technologies publishes its financial results for the first quarter of 2024 and provides an update on its activities DBV Technologies Financial Results Effectiveness Viaskin Peanut Regulatory Affairs Appointment Cash Flow Evolution VITESSE Clinical Trial
PRESS RELEASE published on 05/07/2024 at 22:30, 11 months 6 days ago DBV Technologies Reports First Quarter 2024 Financial Results and Business Update DBV Technologies reports Q1 2024 financial results and business update, with VITESSE enrollment progress, appointment of Chief Regulatory Officer, and $101.5 million cash balance Financial Results Q1 2024 DBV Technologies VITESSE Enrollment Chief Regulatory Officer
Published on 04/14/2025 at 12:30, 12 minutes ago Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting
Published on 04/14/2025 at 12:30, 12 minutes ago Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
Published on 04/14/2025 at 12:00, 42 minutes ago Primary Hydrogen Partners With INRS on Natural Hydrogen in Canada
Published on 04/14/2025 at 12:00, 42 minutes ago Cerrado Gold Provides an Update on Fiscal Policy Changes in Argentina Including Removal of Currency Controls on April 14th
Published on 04/14/2025 at 12:00, 42 minutes ago Snowline Gold Announces Expansion of Leadership Team with Appointment of VP Engineering and Transition of Chief Financial Officer
Published on 04/14/2025 at 11:45, 56 minutes ago Senkron Digital Debuts at WindEurope 2025 with Bold Brand and Transformative Solutions
Published on 04/14/2025 at 08:15, 4 hours 26 minutes ago Aéroports de Paris SA - Filing of the 2024 Universal Registration Document
Published on 04/11/2025 at 18:30, 2 days 18 hours ago Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:00, 2 days 18 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:45, 2 days 18 hours ago NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
Published on 04/11/2025 at 13:49, 2 days 22 hours ago Statement about the number of shares composing the share capital and the number of voting rights as at March 31, 2025
